Urine test for EGFR analysis in patients with non-small cell lung cancer

Franovic, Aleksandra; Raymond, Victoria M.; Erlander, Mark G.; Reckamp, Karen L.

doi:10.21037/jtd.2017.06.144

Cited by 18 publications

(21 citation statements)

References 63 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to its non-invasive nature, one of the advantages of urine is that large volumes can be easily collected for testing. This increased volume has the potential to compensate for targets that may occur in low abundance [28]. However, kit-based methods are either incompatible or prohibitively expensive for use with such high volumes.…”

Section: Resultsmentioning

confidence: 99%

“…Nonetheless, it is notable that a 25ml sample of urine extracted with the current method yielded more nucleic acids than a 50μl dried blood spot sample extracted with Qiagen QIAamp ( S14 Appendix ). This ability to utilize larger volumes may have particular relevance for certain transrenal/cell-free DNAs that have been found to be particularly scarce in urine [28, 29]. It is therefore possible that the use of increased starting material, coupled with purification and amplification of both DNA and RNA with qRTPCR, may help to improve the detection of even very low abundant targets.…”

Section: Discussionmentioning

confidence: 99%

“…While the latter are large in size and correspond predominantly to that of the host (i.e. from the epithelial lining of the urogenital tract), cell-free DNAs are small and enriched for nucleic acids from distant parts of the body, including pathogens and/or disease states [27, 28]. The abundance of cell-free nucleic acids in urine may depend on a number of key variables, including the overall health of the individual, the disease state being evaluated, and the sampling, extraction and detection strategy being employed [25, 27–30].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An efficient and cost-effective method for purification of small sized DNAs and RNAs from human urine

Zainabadi¹,

Dhayabaran²,

Moideen³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Urine holds great promise as a non-invasive sampling method for molecular diagnostics. The cell-free nucleic acids of urine however are small, labile, and difficult to purify. Here an efficient method for the purification of these nucleic acids is presented. An empirically derived protocol was devised by first identifying conditions that allowed recovery of a 100 base pair (bp) DNA, followed by optimization using a quantitative polymerase chain reaction (qPCR) assay. The resulting method efficiently purifies both small sized DNAs and RNAs from urine, which when combined with quantitative reverse transcription PCR (qRTPCR), demonstrably improves detection sensitivity. Fractionation experiments reveal that nucleic acids in urine exist both in the cell-free and cellular fraction, roughly in equal proportion. Consistent with previous studies, amplicons > 180bp show a marked loss in PCR sensitivity for cell-free nucleic acids. Finally, the lysis buffer developed here also doubles as an effective preservative, protecting against nucleic acid degradation for at least two weeks under simulated field conditions. With this method, volumes of up to 25ml of whole urine can be purified in a high-throughput and cost-effective manner. Coupled with its ability to purify both DNA and RNA, the described method may have broad applicability for improving the diagnostic utility of urine, particularly for the detection of low abundant targets.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An efficient and cost-effective method for purification of small sized DNAs and RNAs from human urine

Zainabadi¹,

Dhayabaran²,

Moideen³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…It was also observed that there was a strong disease correlation and the marker performed well as a predictor for overall survival (22,23). There is a growing body of evidences that demonstrates the clear usefulness of urinary DNA (24,25).…”

Section: Original Articlementioning

confidence: 95%

Urinary circulating DNA profiling in non-small cell lung cancer patients following treatment shows prognostic potential

Hu¹,

Shen²,

Huang³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…Similarly, to what has been described in lung cancer [ 108 ], patients may be selected for kinase inhibitors treatment based on urine biopsy. Choudhury et al demonstrated the efficacy of Afatinib in metastatic patients with cancers platinum-refractory presenting ERBB2 and ERBB3 mutations [ 109 ].…”

Section: Predict Targeted Therapy Efficacymentioning

confidence: 99%

Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer

Ferro

Civita

Liotti

et al. 2021

JPM

View full text Add to dashboard Cite

Bladder cancer (BC) is characterized by high incidence and recurrence rates together with genomic instability and elevated mutation degree. Currently, cystoscopy combined with cytology is routinely used for diagnosis, prognosis and disease surveillance. Such an approach is often associated with several side effects, discomfort for the patient and high economic burden. Thus, there is an essential demand of non-invasive, sensitive, fast and inexpensive biomarkers for clinical management of BC patients. In this context, liquid biopsy represents a very promising tool that has been widely investigated over the last decade. Liquid biopsy will likely be at the basis of patient selection for precision medicine, both in terms of treatment choice and real-time monitoring of therapeutic effects. Several different urinary biomarkers have been proposed for liquid biopsy in BC, including DNA methylation and mutations, protein-based assays, non-coding RNAs and mRNA signatures. In this review, we summarized the state of the art on different available tests concerning their potential clinical applications for BC detection, prognosis, surveillance and response to therapy.

show abstract

Urine test for EGFR analysis in patients with non-small cell lung cancer

Cited by 18 publications

References 63 publications

An efficient and cost-effective method for purification of small sized DNAs and RNAs from human urine

An efficient and cost-effective method for purification of small sized DNAs and RNAs from human urine

Urinary circulating DNA profiling in non-small cell lung cancer patients following treatment shows prognostic potential

Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer

Contact Info

Product

Resources

About